FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Medical Devices

Class 1 Recall of Leonard Lang Defibrillation Electrodes

FDA rates as Class 1 a Leonard Lang recall of two Skintact multifunction defibrillation electrode models due to a connector compatibility issue.

Human Drugs

Wound-Healing Study Misses Endpoints

Amicus Therapeutics says top-line Phase 3 ESSENCE study data show its SD-101 wound-healing agent did not meet primary or secondary endpoints in epider...

Human Drugs

Cancer R&D Study Draws Advocate Fire

Industry advocates challenge conclusions in a JAMA Internal Medicine analysis of the cost and potential revenue involved in developing one new cancer ...

Human Drugs

Draft PQ/CMC Standardization Concerns Raised

Drug companies say FDA should do more work on its draft document on standardization of pharmaceutical quality and chemistry, manufacturing, and contro...

Human Drugs

FDA Panel Backs Warning on Gadolinium-based Contrast Agents

FDAs Medical Imaging Drugs Advisory Committee votes to recommend a warning about gadolinium retention for gadolinium-based contrast agents when used d...

Human Drugs

Woodcock Supports Reforms to OTC Monograph Program

CDER director Janet Woodcock tells a House Energy and Commerce Health Subcommittee hearing that the current monograph system for over-the-counter drug...

Human Drugs

Dont Move Imodium from OTC to Rx: CHPA

The Consumer Healthcare Products Association says there is no need for FDA to approve a change for Imodium from over-the-counter to prescription statu...

Human Drugs

Allergan Transfers Restasis Patents to Native American Tribe

Allergan transfers Restasis patents to a Native American tribe to shield them from review by the U.S. Patent Trial and Appeal Board.

Medical Devices

Patch Test for Allergic Contact Dermatitis Approved

FDA approves a SmartPractice PMA for its TRUE Test ready-to-use patch test panels for pediatric patients as young as six years of age for diagnosing a...

Human Drugs

Cardio Drug Approval Rates Drop 52% in 30 Years: Analysis

A Tufts Center for the Study of Drug Development analysis finds that the FDA approval rate for cardiovascular drugs has dropped 52% in the last 30 yea...